Use of Angiotensin-Converting enzyme inhibitors after coronary artery bypass grafting in patients with diabetes mellitus

Bistritz et al discuss their hospital's participation in the Heart Outcomes Prevention Evaluation (HOPE) trial. An audit found that only 57% of participants were taking ACE inhibitors before surgery and only 43% were discharged on an ACE inhibitor, therefore knowledge of the potential benefits...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2003-07, Vol.92 (1), p.77-79
Main Authors: Bistritz, Lana, Amad, Hani, Tandon, Puneeta, Man, Jeremy, Mullen, John C., McAlister, Finlay A.
Format: Article
Language:English
Subjects:
Angiotensin-Converting Enzyme Inhibitors - administration & dosage
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Biological and medical sciences
Cardiology
Cardiovascular disease
Clinical trials
Coronary Artery Bypass
Diabetic Angiopathies - drug therapy
Diabetic Angiopathies - surgery
Enzymes
Guideline Adherence
Hospitals
Humans
Medical Audit
Medical sciences
Pharmaceuticals
Practice Guidelines as Topic
Ramipril - administration & dosage
Ramipril - therapeutic use
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the heart
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bistritz et al discuss their hospital's participation in the Heart Outcomes Prevention Evaluation (HOPE) trial. An audit found that only 57% of participants were taking ACE inhibitors before surgery and only 43% were discharged on an ACE inhibitor, therefore knowledge of the potential benefits of the medication are not enough to ensure the uptake of efficacious therapies.
ISSN:0002-9149
1879-1913
DOI:10.1016/S0002-9149(03)00473-9